Abstract 334P
Background
Immune checkpoint inhibitors (ICI) have been approved for non-small lung cancer (NSCLC). Adrenal insufficiency (AI) is a distinctive adverse event related to ICI. This can be either primary adrenal gland destruction or interference with corticotrophin (ACTH) secretion by the pituitary gland (secondary). As AI is relatively rare and symptoms and signs of AI are non-specific, the diagnosis of AI is often difficult. To clear the incidence and characteristics of AI related with ICI. We conducted a retrospective single center study.
Methods
We reviewed the medical records of patients with NSCLC who received pembrolizumab, nivolumab, atezolizumab or duravalmab at JCHO Kyushu Hospital between Feb 2017 and Jun 2019.
Results
A total of 114 patients with NSCLC received ICI. Eight patients (7.0%) were diagnosed with AI. Median age was 67 (range: 54 to 79). Six were male. Six out of eight patients were secondary AI, one patient was primary AI, and one patient was unknown. The median onset of AI from the first dose of ICI was 203 days (range: 38 to 763). The patients presented with fatigue, fever, nausea, diarrhea and/or dizziness. One patient was diagnosed because of repeating COPD/asthma attack. Hypocholesterolemia, hyponatremia, eosinophilia, hypoglycemia, and hyperkalemia were found 4, 2, 3, 1 and 1 out of 8 patients respectively. One patient didn’t exhibit any above symptom. All of the patients had rapid resolution of symptoms after hydrocortisone replacement.
Conclusions
ICI-associated AI developed in 7.0% of patients requiring hydrocortisone replacement therapy. Symptoms and laboratory abnormalities at the time of onset varied. It is thought that patients using ICI therapy will further increase in the future, and patients who develop ICI-related AI will also increase. Clinicians should deepen their understanding of the nature of AI and provide appropriate information to patients so that AI can be quickly diagnosed and treated.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
504P - A single center report for safety and efficacy of CT-707 in Chinese patients with advanced, anaplastic lymphoma kinase-rearranged non-small cell lung cancer or other tumours
Presenter: Peng Song
Session: Poster display session
Resources:
Abstract
519P - Initial results of lung cancer genomic screening project for individualized medicine in Asia: LC-SCRUM-Asia
Presenter: Chih-Hsi Kuo
Session: Poster display session
Resources:
Abstract
521P - A randomized, phase II study comparing irinotecan versus amrubicin as maintenance therapy after first-line induction therapy for extensive disease small cell lung cancer (HOT1401/NJLCG1401)
Presenter: Keisuke Baba
Session: Poster display session
Resources:
Abstract
526P - A phase II study of apatinib in patients with recurrent/metastatic esophageal squamous cell carcinoma (ESCC)
Presenter: Li Chu
Session: Poster display session
Resources:
Abstract
499P - Prevalence of uncommon epidermal growth factor receptor (EGFR) alterations detected by circulating tumour DNA (ctDNA) in non-small cell lung cancer (NSCLC) patients in Hong Kong
Presenter: Oscar Siu Hong Chan
Session: Poster display session
Resources:
Abstract
489P - Overall survival in patients with EGFRm+ NSCLC receiving sequential afatinib and osimertinib: Updated analysis of the GioTag study
Presenter: Maximilian J. Hochmair
Session: Poster display session
Resources:
Abstract
509P - Second-line treatment after first-line vinorelbine in advanced platinum unfit NSCLC patients: An exploratory analysis of randomized Tempo-Lung trial
Presenter: Andrea Camerini
Session: Poster display session
Resources:
Abstract
500P - Clinico-molecular characteristics of Chinese primary non-small cell lung cancer patients with compound EGFR mutations
Presenter: Jianchun Duan
Session: Poster display session
Resources:
Abstract
527P - A multicenter study of NRG1 fusions in Chinese non-small cell lung cancer patients and response to afatinib using next generation sequencing
Presenter: Xingliang Li
Session: Poster display session
Resources:
Abstract
481P - Updated survival outcomes of the phase II study of low starting dose of afatinib as first-line treatment in patients with EGFR mutation-positive non-small cell lung cancer (KTORG1402)
Presenter: Toshihide Yokoyama
Session: Poster display session
Resources:
Abstract